Latest P53 Stories
Researchers from the Kimmel Cancer Center at Jefferson and two other institutions have discovered new evidence that suggests the "longevity" protein SIRT1, known for its life-spanning effects in different species, can inhibit the development of a known precursor to prostate cancer, prostatic intraepithelial neoplasia (PIN).
Squamous cell carcinoma (SCC) is a common type of skin cancer.
The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team of researchers reports today in the Jan. 4 edition of the Journal of the American Medical Association.
IRVINE, California, and AMSTERDAM, December 22, 2010 /PRNewswire/ -- - This release was originally scheduled for distribution on December 20, 2010, 17.00 CET.
The recently identified TRIM24 protein plays an active role in pushing normal breast cells into rapid cell proliferation and, potentially, into breast cancer.
In studies conducted on the fruit fly, researchers at IRB Barcelona headed by ICREA Professor Marco MilÃ¡n have revealed that organs have the molecular mechanisms to control their proportions.
A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as the "Guardian of the Genome," may do more than thwart cancer-causing mutations.
First clinical trial looks at RG7112 as a way to disable MDM2 in leukemia.
Although p53 is called the â€œguardian of the genomeâ€, having the job of preventing defective cells from dividing, some cancer cells have found a loop hole.
SAN DIEGO, Nov. 16, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany.
- A political dynamiter.